• Alien-Empress Linoleum, Keeper of the Butterflies
    Hailed down from the high heavens seeking perfection. All that was gained was hatred from the universe and neglection
    .................Day dreaming of a happy place where nymphs and faeries play //
  • Archive
  • / Theme
heythereuniverse: Ascidian embryos | wellcome images
neurosciencestuff: Animals in research: zebrafish Zebrafish are probably not the first creatures that come to mind when it comes to animals that are valuable for medical research. You might struggle to imagine you have much in common with this small tropical freshwater fish, though you may be inclined to keep a few “zebra danios” in your home aquarium, given they are hardy, undemanding animals that cost only a few dollars each. Yet each year more and more scientists are turning to zebrafish to unravel the mechanisms underlying their favourite genetic or infectious disease, be it muscular dystrophy, schizophrenia, tuberculosis or cancer. My (conservative) estimate is that zebrafish research is now carried out in at least 600 labs worldwide, including 20 in Australia. So what is it about zebrafish that has taken them from the freshwater rivers and streams of Southeast Asia, beyond the pet shops and into universities and research institutes the world over? A short history of zebrafish A scientist called George Streisinger, working at the University of Oregon in Eugene, USA in the 1970s and 80s, recognised the vast potential of this organism for developmental biology and genetics research. In contrast to fruit flies and worms, the other simple model organisms established at the time, zebrafish are vertebrates. They have a backbone, brain and spinal cord as well as several other organs, including a heart, liver and pancreas, kidneys, bones and cartilage, which makes them much more similar to humans than you may have otherwise thought. But as a vertebrate model, could they be as useful as mice? Several things captured Streisinger’s imagination. Most famously, zebrafish embryos, unlike mouse embryos, develop outside the mother’s body and are transparent throughout the first few days of life. This provides unparallelled opportunities for researchers to scrutinise the fine details of embryonic vertebrate development without first having to resort to invasive procedures or killing the mother. But this advantage is enhanced by the fact zebrafish reproduce profusely (each pair can produce 200-300 fertilised eggs every week); an ideal attribute for genetic studies. Again, the large, external embryos are a critical part of this success. When just one or two cells old, zebrafish embryos can be easily microinjected with mRNA or DNA corresponding to genes of interest; undeterred, they then they go on to grow and reproduce, handing down the injected gene to the next generation. From zebrafish to humans A paper published last month in Nature unveiled the long-awaited sequence of the zebrafish genome, revealing that zebrafish, mice and human have 12,719 genes in common. Put another way, 70% of human genes are found in zebrafish. But even more notable is the finding that 84% of human disease-causing genes are found in zebrafish. Perhaps not surprisingly then, when these genes are injected into zebrafish embryos, the growing animals are doomed to acquire the same diseases. And while zebrafish are still used widely to answer fundamental questions of developmental biology, much current research is directed towards combining their many attributes in studies that are designed to improve human health. This is especially true for cancer research where the expression of cancer-causing genes (oncogenes) can be directed to specific organs, virtually at will. This process, known as transgenesis, is very straightforward in zebrafish and has allowed researchers to produce zebrafish models of liver, pancreatic, skeletal muscle, blood and skin cancers, to name but a few. And when the genomic make-up of these zebrafish tumours is deciphered using the latest DNA sequencing technology, the patterns of mutations, or “gene signatures”, are found to overlap substantially with those in the corresponding human tumours. Trialling cancer drugs These parallels have encouraged researchers to exploit zebrafish in drug development – in particular for high throughput approaches such as chemical/small molecule screens. Here, the ability to generate tens of thousands of zebrafish embryos harbouring the same disease-causing mutations is crucial. Then, as the tumours grow in the synchronously developing larvae, the fish are transferred to small volumes of water containing chemicals that may stop the growth, or better still, kill the cancer cells. Large collections of drugs can be screened relatively quickly for anti-cancer efficacy in this way. One drug, Leflunomide, identified in such a screen is now in early phase clinical trials to kill melanoma cells. The only other drug from a zebrafish chemical screen currently in clinical trials is dimethyl-prostaglandin E2 (dmPGE2). There, the intent is not to kill cancer cells but rather to make mainstream leukaemia treatment more effective. Studies of dmPGE2 increased the number of blood stem cells in zebrafish embryos and it is being trialled now as a way to expand the number of stem cells in human cord blood samples. Human cord blood samples are a valuable commodity to restore bone marrow in leukaemia patients after high dose chemotherapy when a matched bone marrow transplant is unavailable. But the success of this approach is currently limited by the scant number of stem cells in individual cord blood samples, requiring the use of two precious samples for each patient. Tumour growth As well as the transgenic zebrafish models of cancer described above, researchers are also transplanting cells derived from human tumours into zebrafish embryos and watching them grow and spread. The creation of a transparent (non-striped) version of adult zebrafish (called casper, after the cartoon ghost) means the behaviour of tumour cells inside these living organisms can be followed for days at a time. Coupled with the advent of high resolution live-imaging techniques, the birth, growth and spread of tumours can be scrutinised in movies that can be played over and over again. These experiments are usually conducted in zebrafish that have been genetically modified to express genes that glow in specific body compartments, giving researchers the ability to pinpoint potentially critical connections between “host” cells and tumour cells that may determine whether the latter survive or die. This type of experiment is revealing a complex interplay of potentially beneficial and detrimental components. While the proximity of immune cells may instigate mechanisms capable of destroying the tumour, the stimulation of new blood and lymphatic vessel growth towards the tumour is more insidious, since it delivers the tumour with both the nutrients it needs to survive and a network to spread throughout the body. These processes, once properly understood, are likely to provide opportunities for therapeutic intervention in the future. The future of zebrafish Cancer research is just one part of the zebrafish story. In Australia alone, investigators are also using zebrafish to study metabolic disorders such as: diabetes muscle diseases, including muscular dystrophy neurodegenerative disease the response of the host innate immune system to bacterial and fungal infections Excitingly, research is also underway in this country to unravel the genetic mechanisms controlling heart, skeletal muscle and nervous tissue regeneration in zebrafish, in the hope that these processes can be one day recapitulated in humans to address the burgeoning socioeconomic problem of tissue degeneration in our ageing population. So next time you peer into someone’s home aquarium, imagine the biomedical possibilities inherent in this lively and amiable little fish!

i’m so fucking fat i just want to be sick. i hate mirrors

ucsdhealthsciences: Anthophyllite asbestos - U.S. Geological Survey Denver Microbeam Laboratory Banning asbestos—everywhere Writing in an editorial in the May issue of Environmental Health Perspectives, Wael K. Al-Delaimy, MD, PhD, a professor of epidemiology and chief of the Division of Global Health in the Department of Family and Preventive Medicine at UC San Diego School of Medicine, voices support for what he calls a long-overdue appeal by epidemiologists to ban asbestos worldwide. Calling asbestos use a case of “global environmental injustice on a massive scale,” Al-Delaimy underscores the statement by the Joint Policy Committee (JPC) of the Societies of Epidemiology (SE) calling for the global ban of its use. The JPC-SE position is endorsed by its 10 member organizations, along with numerous major epidemiologic and public health associations. For decades, asbestos has been known to cause lung cancer and other respiratory and cancerous conditions. According to Al-Delaimy, asbestos exposure was the number one occupational health problem until its use was banned in most of the developed world. However, an estimated 107,000 people still die each year from occupational exposure to asbestos and 125 million people are exposed to it – risking long-term disease. Although asbestos use has been banned in most high-income countries because of its harmfulness, its use is increasing in middle- and low-income countries. According to the Al-Delaimy, this is because of the effective lobbying of the asbestos industry to prevent policies banning the substance, along with a “profound absence of education and awareness about asbestos’ harm in the countries using it the most.” Likening it to the public health problem of tobacco use, Al-Delaimy said the asbestos industry hires consultants to promote scientific arguments in its favor, manufacture doubt about its risk and attack those advocates and scientists who speak out against the hazards of asbestos. “In addition, the asbestos industry has established markets in countries that have inadequate legislation and weak public health programs and environmental organizations, enabling the sale of asbestos products,” Al-Delaimy writes in the editorial, adding that even countries that discourage use of asbestos-containing products often fail to ban exportation of the deadly products, “as if citizens from the less-developed countries are second-class global citizens.” The personal costs to millions of people who become ill or die from exposure to asbestos products can harm emerging economies, impacting the global economy. More importantly, the practice of higher-income countries and their industries marketing asbestos to poorer, less education countries is unethical, Al-Delaimy said. To remain silent is “unacceptable,” and advocacy by environmental epidemiologists, scientists and public health professionals to ban asbestos is critical to bring legitimacy and accuracy to this important public health issue. Al-Delaimy’s editorial is published in Volume 121 – Number 5, May 2013 issue of the journal Environmental Health Perspectives.
thepredatorblog: Oceanic black tip shark (by JCP van Uffelen)
animals-animals-animals: Sea Anemone Larva (Cerianthus sp.) (by DaniBarchana)

jealous of those who can freely eat without wanting to commit suicide after

heythereuniverse: Compromised blood brain barrier | wellcome images